Abstract 1302
Background
Lorlatinib, a potent, brain-penetrant 3rd-generation (gen) ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved for the treatment of patients (pts) with ALK+ metastatic NSCLC whose disease has progressed on 2nd-gen ALK TKIs. The safety profile of lorlatinib has been previously reported; treatment-related adverse events (AEs) were primarily mild–moderate in severity and manageable through dose modification or standard medical therapy. Here, we report safety data in key subgroups of pts based on age, gender and race.
Methods
This analysis was based on 295 pts with ALK+ or ROS1+ advanced NSCLC, ± CNS metastases, enrolled in the ongoing ph 1/2 trial (NCT01970865) who received lorlatinib 100 mg once daily. All causality AEs were graded per CTCAE v4.03. Data cutoff was 02 Feb 2018.
Results
Of the 295 pts, 241 were aged <65 years (y) and 54 were ≥65 y. AEs were reported at frequencies of 99.6% and 100% in the <65 y and ≥65 y subgroups respectively; however, there were generally more AEs in the ≥65 y subgroup, e.g. anemia (<65 y: 13.7% vs ≥ 65 y: 25.9%), edema (51.5% vs 68.5%), cognitive effects (26.1% vs 40.7%), dyspnea (25.7% vs 37.0%) and fatigue (26.6% vs 35.2%). AEs were generally balanced between males (n = 125) and females (n = 170). Among Asian (n = 108) and non-Asian (n = 161) pts, AEs were reported at a similar incidence (99.1% vs 100%). Grade 3/4 and grade 5 AEs were reported, respectively, in 57.4% and 12.0% of Asian pts and 58.4% and 14.9% of non-Asian pts. There were generally more AEs in non-Asian pts (Table). With multiple dosing, there were no substantial differences in lorlatinib plasma exposure in Asian vs non-Asian pts and neither steady-state AUC nor Cmax met the threshold for dose-adjustment.Table:
1542P
Racea | ||
---|---|---|
AEs with >10% difference between groups, n (%) | Asian (n = 108) | Non-Asian (n = 161) |
Hypertriglyceridemiab | 82 (75.9) | 92 (57.1) |
Edemab | 52 (48.1) | 97 (60.2) |
Peripheral neuropathyb | 41 (38.0) | 82 (50.9) |
Cognitive effectsb | 18 (16.7) | 53 (32.9) |
Weight increased | 15 (13.9) | 46 (28.6) |
Mood effectsb | 13 (12.0) | 45 (28.0) |
Fatigueb | 8 (7.4) | 59 (36.6) |
Anemia | 7 (6.5) | 35 (21.7) |
Pain in extremity | 7 (6.5) | 30 (18.6) |
AEs reported in descending order of frequency in Asian pts.
aUnspecified race (n = 26)
bClustered term comprising AEs that represent similar clinical symptoms/syndromes.
.Conclusions
There were no clinically relevant differences in the AEs based on age or gender. The frequencies of most AEs known to be associated with lorlatinib were generally lower in Asian than in non-Asian pts; however, hypertriglyceridemia was more frequently reported in Asian vs non-Asian pts.
Clinical trial identification
NCT01970865.
Editorial acknowledgement
Jade Drummond of inScience Communications, Springer Healthcare (Chester, UK); funded by Pfizer Inc.
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: Guardant Health; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Research grant / Funding (institution): Fundación Merck Salud; Research grant / Funding (institution): EMD Serono. B.J. Solomon: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Eisai; Licensing / Royalties: Veristrat (Biodesix); Licensing / Royalties: UpToDate; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Institution: Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution), Institution: Pfizer; Advisory / Consultancy, Institution: Genentech. B. Besse: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Onxeo; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Inivata; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Biogen; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Merck; Research grant / Funding (institution): MSD Oncology; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): PharmaMar; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Spectrum Pharmaceuticals; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Tiziana Therapeutics. T.M. Bauer: Full / Part-time employment: Tennessee Oncology; Full / Part-time employment: Sarah Cannon Research Institute; Advisory / Consultancy: Guardant Health; Advisory / Consultancy, Research grant / Funding (institution): Loxo Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Institution: Ignyta; Advisory / Consultancy, Institution: Moderna Therapeutics; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Medpacto, Inc.; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Leap Therapeutics; Research grant / Funding (institution): MabVax; Research grant / Funding (institution): Stemline Therapeutics; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): Merrimack Pharmaceuticals; Research grant / Funding (institution): Immunogen; Research grant / Funding (institution): Millennium Pharmaceuticals; Research grant / Funding (institution): Calithera Biosciences; Research grant / Funding (institution): Kolltan Pharmaceuticals; Research grant / Funding (institution): Principa Biopharma; Research grant / Funding (institution): Peleton; Research grant / Funding (institution): Immunocore; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Aileron Therapeutics; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Five Prime Therapeutics; Research grant / Funding (institution): Jacobio; Research grant / Funding (institution): Top Alliance BioScience; Research grant / Funding (institution): Janssen Pharmaceuticals; Research grant / Funding (institution): Clovis Oncology; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Karyopharm Therapeutics; Research grant / Funding (institution): Onyx Pharmaceuticals; Research grant / Funding (institution): Phosplati Therapeutics; Research grant / Funding (institution): Foundation Medicine. R.A. Soo: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Merck Sharp & Dohme; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Yuhan; Honoraria (self), Advisory / Consultancy: Celgene. D.R. Camidge: Honoraria (self): Roche; Honoraria (self): G1 Therapeutics; Honoraria (self): Mersana; Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self): AstraZeneca; Honoraria (self): Genoptix; Honoraria (self): Ignyta; Honoraria (self): Daiichi Sankyo; Honoraria (self): Hansoh; Honoraria (self): Lycera; Honoraria (self): Biothera; Honoraria (self): Revolution Medicines. R. Chiari: Speaker Bureau / Expert testimony: Takeda. A. Bearz: Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis. C. Lin: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self): Roche; Honoraria (self), Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Blueprint Medicines; Travel / Accommodation / Expenses: Eli Lilly; Travel / Accommodation / Expenses: BeiGene. S.M. Gadgeel: Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: ARIAD Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: Takeda; Research grant / Funding (self), Research grant / Funding (institution): Merck; Research grant / Funding (institution): Blueprint Medicines. E. Tan: Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim. T. Seto: Honoraria (self), Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Honoraria (self), Research grant / Funding (institution): Kissei Pharmaceutical; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Pfizer Japan; Honoraria (self), Research grant / Funding (institution): YakultHonsha; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Mochida Pharmaceutical; Honoraria (self): Nippon Kayaku; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Roche Singapore; Honoraria (self): Sanofi; Honoraria (self): Showa Yakuhin Kako; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Takeda Pharmaceutical; Research grant / Funding (institution): Bayer Yakuhin; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Novartis Pharma; Research grant / Funding (institution): Verastem. G.R. Oxnard: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Inivata; Advisory / Consultancy: Janssen; Advisory / Consultancy: Loxo; Honoraria (self): Foundation Medicine. G. Peltz: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. A. Abbattista: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. H. Thurm: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. F. Toffalorio: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. S.I. Ou: Advisory / Consultancy, Shareholder / Stockholder / Stock options: TP Therapeutics; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Honoraria (self), Research grant / Funding (institution): Ariad Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Foundation Medicine; Honoraria (self): Merck; Advisory / Consultancy, Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Revolution Medicines. A.T. Shaw: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech; Honoraria (self): Foundation Medicine; Honoraria (self): Guardant Health; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (institution): ARIAD Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Ignyta; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: KSQ Therapeutics; Advisory / Consultancy: Natera; Advisory / Consultancy: Loxo Pharmaceuticals; Advisory / Consultancy: Takeda; Advisory / Consultancy: Bayer; Advisory / Consultancy: Chugai Pharma; Research grant / Funding (institution): TP Therapeutics.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract